Completed PHASE2 INTERVENTIONAL 3-arm NCT02679456

Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis

A Multicenter, Randomized, Evaluator Blinded, Active-Controlled Study to Evaluate the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis

Sponsor: Scynexis, Inc.

Conditions Vulvovaginal Candidiasis

Interventions Fluconazole SCY-078

Updated 8 times since 2017 Last updated: Jul 10, 2019 Started: Nov 30, 2015 Primary completion: Aug 5, 2016 Completion: Aug 5, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Vulvovaginal Candidiasis and is currently completed. Scynexis, Inc. leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Aug 2019 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Mar 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2017 — Mar 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Scynexis, Inc.
ethica Clinical Research Inc.

Data source: Scynexis, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Santo Domingo, Dominican Republic